Regeneron Q1 Profit and Revenue Beat on Dupixent Sales, Shares Slip
Regeneron posted first-quarter profit and revenue that topped consensus forecasts, driven by solid sales of its eczema therapy Dupixent, yet its shares dipped marginally in premarket trading. Robust Dupixent demand accounted for the core revenue beat, reinforcing the drug’s status as the primary growth engine for Regeneron heading into the next quarter.
1. First-Quarter Results Exceed Expectations
Regeneron delivered first-quarter net income and revenue above analyst forecasts, driven primarily by strong demand for Dupixent, its eczema therapy. Management indicated that Dupixent sales accounted for the majority of revenue growth, highlighting continued pricing strength and market penetration.
2. Premarket Stock Movement
Despite the positive results, Regeneron shares slipped slightly in premarket trading, reflecting broader investor caution ahead of major technology earnings. Market participants are now turning their attention to upcoming data readouts and pipeline milestones beyond Dupixent.